SCHEMBL4240132

SCHEMBL4240132

CCOC(=O)C(C)(C)CNC(=O)OC(C)(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
ALDH1A1 P00352 1/20 0.46
TSHR P16473 1/20 0.46
CYP4F2 P78329 1/20 0.42
CYP4A11 Q02928 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
GAA P10253 1/20 0.40
PKM P14618 3/20 0.40
KDM4E B2RXH2 1/20 0.40
HTT P42858 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
CA12 O43570 3/20 0.39
CA1 P00915 3/20 0.39
CA2 P00918 2/20 0.39
CA9 Q16790 2/20 0.39
PTPRB P23467 2/20 0.39
THRB P10828 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21424112 0.86 TDP1 (0.46) MEN1KMT2AALDH1A1TSHRTDP1
SCHEMBL21974303 0.86 TDP1 (0.42) MEN1KMT2AALDH1A1TSHRTDP1
SCHEMBL21423585 0.84 TDP1 (0.41) MEN1KMT2AALDH1A1TSHRTDP1
SCHEMBL14684133 0.83 DGAT1 (0.47) MEN1KMT2AALDH1A1TSHRTDP1
SCHEMBL1332098 0.83 DGAT1 (0.47) MEN1KMT2AALDH1A1TSHRTDP1
SCHEMBL17141202 0.83 MEN1 (0.44) MEN1KMT2AALDH1A1TSHRTDP1
SCHEMBL10475927 0.80 MEN1 (0.42) MEN1KMT2AALDH1A1TSHRTDP1
SCHEMBL11989395 0.79 TDP1 (0.46) MEN1KMT2AALDH1A1TSHRTDP1
SCHEMBL17891860 0.78 CYP4F2 (0.44) MEN1KMT2AALDH1A1TSHRCYP4F2
SCHEMBL1444341 0.77 MEN1 (0.49) MEN1KMT2ATDP1GAACA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11365192-B2 Pyridine compound substituted with azole TAISHO PHARMACEUTICAL CO., LTD. (JP) 2022-06-21 US disclosed
US-20210122741-A1 PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE TAISHO PHARMACEUTICAL CO., LTD (JP) 2021-04-29 US disclosed
EP-3666766-A1 PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE Taisho Pharmaceutical Co., Ltd. (JP) 2020-06-17 EP disclosed
US-20200138964-A1 TERTIARY AMINE COMPOUND OR IMINE COMPOUND-POLYMER CONJUGATE AND PRODUCTION METHOD THEREFOR SEIKAGAKU CORPORATION (JP) 2020-05-07 US disclosed
CN-110914254-A Azole-substituted pyridine compound 大正制药株式会社 2020-03-24 CN disclosed
EP-3083597-B1 FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES AS CAV2.2 CALCIUM CHANNEL BLOCKERS GRUENENTHAL GMBH (DE) 2017-11-22 EP disclosed
EP-3083597-B1 FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES AS CAV2.2 CALCIUM CHANNEL BLOCKERS GRUENENTHAL GMBH (DE) 2017-11-22 EP disclosed
US-9562036-B2 Fluoromethyl-substituted pyrrole carboxamides as CaV2.2 calcium channel blockers Grünenthal GmbH (DE) 2017-02-07 US disclosed
EP-2834220-B1 4-HYDROXY-ISOQUINOLINE COMPOUNDS AS HIF HYDROXYLASE INHIBITORS FIBROGEN INC (US) 2016-11-09 EP disclosed
EP-3083612-A1 FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES AS CAV2.2 CALCIUM CHANNEL BLOCKERS Grünenthal GmbH (DE) 2016-10-26 EP disclosed
EP-1572693-A1 MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITING COMPOUNDS Pharmacia Corporation (US) 2005-09-14 EP disclosed
WO-2005068472-A1 TRICYCLIC BENZAZEPINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS USED FOR THE TREATMENT OF CARDIOVASCULAR DISEASES BAYER HEALTHCARE AG (DE) 2005-07-28 WO disclosed
US-20040209897-A1 Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds PHARMACIA CORPORATION 2004-10-21 US disclosed
WO-2004058762-A1 MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITING COMPOUNDS PHARMACIA CORPORATION (US) 2004-07-15 WO disclosed
US-6376230-B1 Stereoselective process for producing intermediates of cryptophycins ELI LILLY AND COMPANY 2002-04-23 US disclosed
EP-1127055-A2 STEREOSELECTIVE PROCESS FOR PRODUCING CRYPTOPHYCINS ELI LILLY AND COMPANY (US) 2001-08-29 EP disclosed
EP-0929535-A4 PROCESS AND NOVEL INTERMEDIATES LILLY CO ELI (US) 2001-05-23 EP disclosed
WO-2000023429-A2 STEREOSELECTIVE PROCESS FOR PRODUCING CRYPTOPHYCINS ELI LILLY AND COMPANY (US) 2000-04-27 WO disclosed
EP-0929535-A1 PROCESS AND NOVEL INTERMEDIATES ELI LILLY AND COMPANY (US) 1999-07-21 EP disclosed
WO-1998009955-A1 PROCESS AND NOVEL INTERMEDIATES ELI LILLY AND COMPANY (US) 1998-03-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210122741-A1 PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE CYP2C19, CYP4A11, CYP11B1 MEN1 1907/4885KMT2A 813/4885ALDH1A1 378/4885
US-11365192-B2 Pyridine compound substituted with azole CYP2C19, CYP4A11, CYP11B1 MEN1 1907/4885KMT2A 813/4885ALDH1A1 378/4885
US-20040209897-A1 Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds MAPKAPK2, MAP3K2, MKNK2 MEN1 2315/4885KMT2A 1540/4885ALDH1A1 4638/4885
US-20200138964-A1 TERTIARY AMINE COMPOUND OR IMINE COMPOUND-POLYMER CONJUGATE AND PRODUCTION METHOD THEREFOR SOAT1, SLC7A1, ODC1 MEN1 236/4885KMT2A 939/4885ALDH1A1 1001/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.